Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (May 22nd Preview)
-
FDA approval for a new TROP2 ADC in triple-negative breast cancer
The FDA approved Datroway (TROP2-directed antibody-drug conjugate) as a first-line treatment option for triple-negative breast cancer, advancing Daiichi Sankyo and AstraZeneca’s ADC strategy in an area with persistent unmet need. The approval marks Datroway’s third FDA action, after prior indications, and positions the companies to compete more directly in the TROP2 space. The decision gives Datroway label momentum as rivals also push TROP2 ADC combinations across solid tumors. For investors and clinicians, the key near-term focus is how the Datroway line-extension plays out versus existing first-line regimens and emerging combination approaches. Datroway’s advancement also underscores the growing emphasis on biomarker-defined patient selection within breast cancer subtypes, particularly in therapy lines that traditionally have limited targeted options.
-
ASCO 2026 Phase 3 data sets up a frontline NSCLC benchmark fight for sac-TMT
Merck and Kelun-Biotech’s TROP2-directed ADC sacituzumab tirumotecan (sac-TMT) delivered a major Phase 3 progression-free survival result in first-line, PD-L1-positive non-small cell lung cancer, cutting the risk of disease progression or death by 65% versus Keytruda alone, according to an ASCO 2026 abstract. In the OptiTROP-Lung05 study in China, median PFS was not reached in the combo arm after a median follow-up of 10.5 months, compared with 5.7 months for Keytruda monotherapy. Response rates were reported at just over 70% for the combination versus 42% with Keytruda alone, with discontinuation rates lower than or comparable to the control arm. While OS data were not mature at the data cutoff, the magnitude of the PFS readout—paired with the randomized Phase 3 design—raises the stakes for how ADC–PD-1 combinations could reshape treatment sequencing in frontline lung cancer.
-
Biogen and Denali abandon LRRK2 approach after Phase 2b failure in Parkinson’s
Biogen and Denali Therapeutics dropped BIIB122 in idiopathic Parkinson’s after a Phase 2b trial missed its primary endpoint, according to updated results reported to industry. The randomized study enrolled 648 adults with Parkinson’s, testing placebo versus BIIB122, a pill designed to target the LRRK2 protein. The readout deals a setback to a strategy that has been widely discussed since genetic evidence linked LRRK2 mutations to inherited Parkinson’s and since prior work suggested blocking LRRK2 could benefit broader patient populations. Denali plans to continue independently a separate study focused on a specific subset of Parkinson’s patients, keeping the broader question of whether patient enrichment or disease stage can restore clinical signal for LRRK2 inhibition.
-
Retatrutide’s Phase 3 obesity results strengthen Lilly’s triple-agonist position
Eli Lilly reported Phase 3 results for retatrutide (a triple-agonist targeting GIP/GLP-1/glucagon receptors), showing dose-dependent weight loss up to 28% over 80 weeks in its Triumph-1 trial, with the company highlighting tolerability performance relative to placebo. The readout included a low-dose arm that achieved 19% average weight loss. Lilly enrolled 2,339 participants with obesity and a non-diabetic complication, randomizing patients to weekly 4 mg, 9 mg, 12 mg retatrutide, or placebo. Nearly 500 patients moved into an extension, with follow-up reported through 104 weeks for that subset. The company’s data reinforce retatrutide’s positioning ahead of regulatory submissions and place pressure on obesity rivals as competition intensifies around multi-receptor GLP-1/GIP strategies and next-generation candidates.
-
Gene therapy and regulatory pipeline: FDA clearance for Qihan Biotech’s universal allogeneic CAR T
Hangzhou Qihan Biotech received FDA IND clearance for QT-019C, a universal allogeneic CAR T-cell therapy designed for autoimmune diseases. The therapy is engineered to stably express two CARs targeting CD19 and BCMA and is built from healthy-donor leukapheresis products to enable an off-the-shelf approach. The clearance sets the stage for clinical evaluation in the US, where autoimmune CAR T remains a heavily watched space given safety constraints and the need for scalable manufacturing. QT-019C’s dual-target construct reflects an emphasis on broadened antigen coverage and may also inform how future allogeneic designs address durability and relapse risk as developers move beyond early preclinical and single-target formats.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.